Avelumab fails to improve survival in gastric cancer

29th November 2017 Uncategorised 0

Merck and Pfizer have revealed that a Phase III trial assessing avelumab in patients with gastric cancer after two prior therapeutic regimens failed to hit its primary target of showing an improvement in survival.

More: Avelumab fails to improve survival in gastric cancer
Source: News